Theralizumab | TGN1412 | TAB-08 | TABO8

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
1 mg	3-5days	$719.00	Visible after login	- +
5 mg	3-5days	$1880.00	Visible after login	- +

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

1 mg

3-5days

$719.00

Visible after login

- +

5 mg

3-5days

$1880.00

Visible after login

- +

Product Overview

Product Name	Theralizumab \| TGN1412 \| TAB-08 \| TABO8
CAS	906068-56-2
Storage condition	store at -20°C \| Shipping with blue ice.

Product details

Theralizumab (TGN1412) is a humanized lgG4 superagonistic anti-CD28 monoclonal antibody that directly stimulates T cells. Theralizumab can cause cytokine release syndrome (CRS). Theralizumab can be used for the research of rheumatoid arthritis.

Related literature

From TGN1412 to TAB08: the return of CD28 superagonist therapy to clinical development for the treatment of rheumatoid arthritis.

PMID: 27586803

The rise and fall of the CD28 superagonist TGN1412 and its return as TAB08: a personal account.

PMID: 27191544 DOI: 10.1111/febs.13754

Sorry, no related items

History

Icrucumab (Anti-VEGFR1 / FLT1)

1024603-92-6 95+%

CLA1681

Theralizumab | TGN1412 | TAB-08 | TABO8

906068-56-2 95+%

HL1789

Scopoletin acetate | 7-Acetoxy-6-methoxycoumari

56795-51-8 98+%

Theralizumab | TGN1412 | TAB-08 | TABO8

Chemical safety data sheet(MSDS)